Q2 2026 results exceeded expectations, with strong Medicare and Optum Health performance, while commercial cost trends remain elevated. Full-year EPS guidance was raised, and significant investments in AI and modernization continue. Durable earnings and a 13%-16% long-term growth target were reaffirmed.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.